Adams HJA, Kwee TC. Prognostic value of pretransplant FDG-PET in refractory/relapsed Hodgkin lymphoma with autologous stem cell transplantation : systematic review and meta-analysis. Ann Haematol. 2016 Apr;95(5):695-706.
Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma:3 year study results. Blood 2021; 138(6):427-438.
Armand P, Chen YB, Redd RA, et al. PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. Blood 2019;134(1):22-29.
Herrera AF, Chen L, Nieto Y, et al. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma a multicentre phase 2 trial. Lancet Haematol. 2023 Jan;10(1):e14-e23.
LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood 2018 Jul 5;132(1):40-48.
Marouf A, Cottereau AS, Kanoun S, et al. Outcomes of refractory or relapsed Hodgkin‘s lymphoma patients with pos-autologous stem cell transplantation brentuximab vedotin maintenance: a French multicenter observational cohort study. Haematologica 2022;107(7):1681-1686.
Moskovitz AJ, Yahalom J, Kewalramani T, et al. Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma. Blood 2010;116(23):4934-4937.
Moskowitz CH, Nademanee A, Masszi T, et al. AETHERA Study Group. Brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomized, doubleblind, placebo-controlled, phase 3 trial. Lancet 2015;395(9980):1853-1862.
Moskowitz AJ, Shah G, Schröder H, et al. Phase II trial of pembrolizumab in combination with Gemcitabine, Vinorelbine and Liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 2021;39(28):3109-3117.
Santoro A, Mazza R, Pulsoni A, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020 Jan 14;4(1):136-140.
Van Den Neste E, Casasnovas O, André M, et al, Haematologica 2013 Aug;98(8):1185-95.
Wilke C, Cao Q, Dusenbery KE, et al. Role of consolidative radiation therapy after autologous stem cell transplantation for the treatment of relapsed or refractory Hodgkin lymphoma. Int J Radiat Oncol Biol Phys. 2017;99(1):94-102.